William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

The bank's list of highest-conviction stock picks for 2026 spans numerous sectors and features names including Pepsi and GM.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's ...

This stock is a great choice for cautious and aggressive investors.

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

An investor whose portfolio contains some value- or income-focused investments and some growth-oriented investments, who ...